Updated
Revised
and
The Biotechnology Education Company ®
EDVOTEK, Inc. • 1-800-EDVOTEK • www.edvotek.com
EVT 001227K
EDVO-Kit #
314In Search of the Cancer Gene
Storage: See Page 3 for specifi c storage instructions
EXPERIMENT OBJECTIVE:
In this experiment, students will gain an understanding of the effect of mutations in the p53 tumor suppressor
gene and its role in familial cancers.
This experiment is designed for DNA staining with InstaStain® Ethidium Bromide.
In Search of the Cancer Gene
EVT 001227K
2
xxx314EDVO-Kit #
EDVOTEK - The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVOTEK, The Biotechnology Education Company, and InstaStain are registered trademarks of EDVOTEK, Inc.. Ready-to-Load and UltraSpec-Agarose are trademarks of EDVOTEK, Inc.
Page
Experiment Components 3Experiment Requirements 4Background Information 5
Experiment Procedures Experiment Overview and General Instructions 12 Module One: Construction of a Family Pedigree 13 Module Two: Separation of DNA Fragments 14 Module Three: Analysis of Autorads to Search for p53 Mutagens 17 Study Questions 18 Instructor's Guidelines Notes to the Instructor 19 Experiment Results and Analysis 23 Study Questions and Answers 25
Appendices
A Agarose Gel Preparation For DNA Staining with InstaStain® Ethidium Bromide 28
B Quantity Preparations for Agarose Gel Electrophoresis 29 C Staining and Visualization of DNA with InstaStain® Ethidium Bromide Cards 30
Material Safety Data Sheets 31
Table of Contents
In Search of the Cancer Gene
EVT 001227K
3
EDVOTEK - The Biotechnology Education Company® 1-800-EDVOTEK • www.edvotek.com
FAX: (301) 340-0582 • email: [email protected]
314EDVO-Kit #
Experiment Components
All components are intended for educational research only. They are not to be used for diagnostic or drug purposes, nor admin-istered to or consumed by humans or animals.
THIS EXPERIMENT DOES NOT CONTAIN HUMAN DNA. None of the experi-ment components are de-rived from human sources.
Ready-to-Load Samples for Electrophoresis
A Standard DNA Fragments B Control DNA C Patient Peripheral blood DNA D Patient Breast Tumor DNA E Patient Normal Breast Tissue DNA
Reagents & Supplies
• X-ray simulated p53 hot spot sequences • UltraSpec-Agarose™ powder • Concentrated electrophoresis buffer • InstaStain® Ethidium Bromide
This experiment contains reagents for 6 groups.
This experiment is designed for DNA staining with InstaStain® Ethidium Bromide.
Components & Requirements
Before use, check all volumes of Standard DNA fragments and DNA samples for electrophoresis. Evaporation may have caused samples to become more concentrated.
If needed, tap tubes or centrifuge, then add distilled water to slightly above the 1.0 cm level and mix.
Storage: All DNA samples can be stored in the refrigerator
4.1
cm
ApproximateVolume
Measurements
0.5 cm tube120 µl
1.0
cm
In Search of the Cancer Gene
EVT 001227K
4
xxx314EDVO-Kit #
EDVOTEK - The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Mon - Fri 9 am - 6 pm ET
(1-800-338-6835)
EDVO-TECH SERVICE
1-800-EDVOTEK
Mon - Fri9:00 am to 6:00 pm ET
FAX: (301) 340-0582Web: www.edvotek.comemail: [email protected]
Please have the following information ready:
• Experiment number and title• Kit lot number on box or tube• Literature version number (in lower right corner)• Approximate purchase date
Technical ServiceDepartment
Online Orderingnow available
Visit our web site for information about EDVOTEK’s complete line of “hands-on” experiments forbiotechnology and biology education.
Requirements
• Horizontal gel electrophoresis apparatus • D.C. power supply • Automatic micropipets with tips • Balance • Microwave, hot plate or burner • Pipet pump • 250 ml fl asks or beakers • Hot gloves • Safety goggles and disposable laboratory gloves • Distilled or deionized water • UV Transilluminator
5In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
Backg
rou
nd
Info
rmatio
n
About Family Pedigrees
• A Circle represents a female.
• A square represents a male. • A shaded circle or square refers to a per-
son having some form of cancer.
• An open (non-shaded) square or circle represents a person who is free of cancer.
• A circle or square (either shaded or open)
with a diagonal slash through it repre-sents a person who is deceased.
In Li-Fraumeni syndrome, the pattern of cancers in family pedigrees suggest dominant inheritance. It is a genetic predisposition leading to specifi c types of cancers. Typically, the onset of cancer is at an early age, with multiple primary tumors.
When drawing a family pedigree, the following are general guidelines to the symbols used and their representations:
Female free of cancer
Male free of cancer
Female with some form of cancer
Male with some form of cancer
Female , deceased
Male, deceased
or
or
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
6
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #B
ackg
rou
nd
Info
rmat
ion
The Role of Genes in Cancer
Many contributory factors have been identifi ed to cause the onset of cancer that include exposure to certain carcinogens in our diets and environment. Several forms of cancer have familial predisposition. These cancers appear to be linked to inherited mutation of suppressor genes, such as p53.
Hereditary SporadicGermline Mutation Somatic Mutation
Multiple Tumors
Bilateral Tumors
Early onset
Somatic Mutation
Single Tumors
Unilateral Tumors
Later onset
Normal Gene
First Somatic Mutation
Second Somatic Mutation
Figure 1: Hereditary and Sporadic Models of Gene Inactivation.
Familial cancers constitute a very small fraction of the total reported cancers and occur in dominant inherited patterns. Mutations that are directly inher-ited are referred to as germline mutations. Such mutations can be detected in familial pedigrees. A second type of mutation, known as somatic mutations, do not have direct genetic links and are acquired during the life of the individual. Patterns of typical hereditary and sporadically ac-quired nonhereditary pedigrees appear in Figure 1.
In a germline with an inherited mutation, a single somatic muta-tion within a suppressor gene will result in the inactivation of both alleles. By contrast, nor-mal inherited suppressor genes, that are free of mutations, will require two sequential mutations to initiate tumors. This model is referred to as the "Two-hit" hypothesis.
Historically, some of the fi rst genes identifi ed include the reti-noblastoma (RB) gene, Wilm's’ tumor (WTI), neurofi bromatosis type II gene and Li-Fraumeni syn-drome. In Li-Fraumeni syndrome, a notable feature in family pedi-grees, include a sarcoma patient and at least two immediate rela-
tives with other cancers before the age of 45, as well as multiple cancers in other family members. This is illustrated in fi gure 2.
7In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
Backg
rou
nd
Info
rmatio
n
The Role of Genes in Cancer
With the advent of molecular biology applications to medicine, gene maps and the chromosomal locations of genes are available as tools for the identifi cation of predisposition for various diseases. The procedures used to obtain such information include DNA isolation and the analysis of point mutations in hot spot areas in cancer-related genes, such as p53. Several methods of analysis for the detection of point mutations in genes include DNA sequencing.
BB.42
BR.36 SS.23BB.34
CN.2 CN.36
OS.13 LK.2
BB Bilateral breast cancerBR Breast cancerCN Brain tumorLK LeukemiaOS Osteosar comaSS Soft tissue sar coma
Figure 2: Example of a Li-Fraumeni family pedigree.
The Human Genome Project has provided information to link identifi cation of various cancers and other diseases to DNA sequenc-ing information. This information needs to be handled cautiously to assure confi dential-ity of patient genetic profi les.
The study of inherited cancers has given cancer molecular biologists the opportunity to search for genes that are critical in normal cell development and carcinogenesis. At the molecular level, cancer formation is char-acterized by alterations in both dominant oncogenes and tumor suppressor genes, such as p53. Suppressors are normal cellular proteins that are involved in limiting cell growth. By contrast, oncogenes are involved in promoting the growth of cells.
In recent years, the p53 tumor suppressor protein has become the center of many cancer biology studies. Because it appears to be of major signifi -cance, there is great impetus to study how this gene functions in normal cells compared to cancer cells. The gene for the p53 protein is located on the short arm of chromosome 17. It encodes a normal 53,000 molecular nuclear phosphoprotein. Wild type p53 functions as a cell regulator. There is now well-documented evidence that normal p53 is a sequence-specifi c DNA-bind-ing protein that is a transcriptional regulator. Upon introduction of muta-tions, p53 loses its ability to bind to DNA. By contrast, p53 that have muta-tions in specifi c hot spots promote uncontrolled cell growth and therefore function as oncogenes. For a tumor suppressor gene such as p53 to play a role in transformation in cancer, both alleles need to be altered, as shown in fi gures 1 and 2.
The p53 protein can be divided into three domains. The fi rst is the amino terminus region which contains the transcriptional activation region. The second is the central region within the protein where the majority of critical "hot spot" mutations are located. These "hot spots" are sites where muta-
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
8
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #B
ackg
rou
nd
Info
rmat
ion
The Role of Genes in Cancer
tions are detected in high frequencies. They are between exons 5 through 8 where 95% of the mutations occur. Within this region there are fi ve sub-regions where point mutations are detected in human cancers. The third region of the p53 protein is the carboxyl section, the most complex section that contains the oligomerization and nuclear localization sequences.
Examples of hot spots include codons 165 and 175 in exon 5; 196 and 213 in exon 6; 245 and 248 in exon 7; 273 and 282 in exon 8; all are within the p53 protein. Several of these mutations result in an altered p53 protein confor-mation. In turn, these changes can result in increased stability of the mutant protein and the ability to bind to the normal p53 protein and inactivate it. It is of interest to note that there are correlations between mutation and tumor tissue. One example is the mutation at amino acid 175 which is com-mon in colon carcinoma but is rarely observed in lung carcinoma. The inherited Li-Fraumeni syndrome as it has become to be known is rare. When it does occur it affects young family members and results in high mor-tality rates. Two physicians, Li and Fraumeni fi rst described the syndrome after examining death certifi cates of 648 childhood sarcomas. It was discov-ered in four families where siblings and cousins had childhood sarcomas. Further analysis showed more than 50% of the affected families had extend-ed phenotypes that included brain, breast cancers and leukemias. Cells from individuals with LFS have only a single wild type p53 allele. Examination of their p53 gene have shown correlations of the cancers to mutations in the protein as described above.
OVERVIEW OF POLYMERASE CHAIN REACTION:
PCR has two important advantages. The fi rst is sensitivity, which allows for DNA fi ngerprinting identifi cation using much smaller amounts of DNA since PCR amplifi es DNA. The second advantage is the speed of PCR analysis, which allows critical questions to be answered more quickly as compared to Southern Blot analysis.
PCR amplifi cation requires the use of a thermostable DNA polymerase, such as Taq polymerase. Purifi ed from a bacterium known as Thermus Aquaticus that inhabits hot springs, Taq polymerase is commonly used in PCR because it remains stable at near-boiling temperatures. Also included in the PCR reaction are the four deoxynucleotides (dATP, dCTP, dGTP, and dTTP) and two synthetic oligonucleotides, typically 15-30 base pairs in length, known as "primers". These components, together with the DNA to be amplifi ed, are incubated in an appropriate buffer that contains Mg2+. The primers are designed to correspond to the start and end of the DNA to be amplifi ed, known as the "target".
9In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
The Exp
erimen
t
The Role of Genes in Cancer
3' 5'
3' 5'
5' 3'
5' 3'
5'
5' 3' 3' 5'
5' 3'
5' 5'
Denature 94°C
5'
Extension72°C
3' 5'
Separation of 2 DNA strands
=
Primer 1 =
Primer 2 =
5' 3' 5'
Anneal 2 primers
45°C
3' 5' 5'
5' 5'
3' 5' 5'
5'
5' 3'
5'
5' 5'
5' 3'
5' 3'
5' 3'
5' 3'
5' 3'
5' 3'
5'
5' 3'
Cyc
le 1
C
ycle
2
Cyc
le 3
Target Sequence
5' 3'
5' 3'
5' 3'
Figure 3: The Polymerase Chain Reaction
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
10
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #Th
e Ex
per
imen
t
The PCR reaction mixture (which contains the DNA polymerase, buffer, deoxynucleotides, primers, and template) is subjected to sequential heating/cooling cycles at three different temperatures (Figure 3).
• In the fi rst step, the enzyme reaction is heated to near boiling (92° - 96°C.) to denature or "melt" the DNA. This step, known as "denatur-ation" disrupts the hydrogen bonds between the two complimentary DNA strands and causes their separation.
• In the second PCR step, the mixture is cooled to a temperature that is typically in the range of 45° - 65°. In this step, known as "annealing", the primers, present in great excess to the template, bind to the sepa-rated DNA strands.
• In the third PCR step, known as "extension", the temperature is raised to an intermediate value, usually 72°C. At this temperature the Taq polymerase is maximally active and adds nucleotides to the primers to synthesize the new complimentary strands.
OVERVIEW OF DNA SEQUENCING:
During DNA sequence analysis, four separate enzymatic reactions are per-formed, one for each nucleotide. Each reaction contains DNA polymerase, the single-stranded DNA template to be sequenced and to which the synthetic DNA primer has been hybridized, the four deoxyribonucleotide tri-phosphates (dATP, dGTP, dCTP, dTTP), 32P labeled or fl uorescent nucleotide(s) are added for the detection of growing DNA fragments (Figure 4), and the appropriate buffer for in vitro DNA synthesis.
In sequencing reactions, the “G” reaction contains dideoxyGTP, the “C” reac-tion dideoxyCTP, the “A” reaction dideoxyATP, and the “T” reaction dide-oxyTTP. The dideoxynucleotide concentrations are carefully adjusted so that they are incorporated into a growing DNA strand randomly and infrequent-ly. Once a dideoxynucleotide is incorporated into the growing DNA strand, DNA synthesis is terminated. The site of the dideoxynucleotide incorpora-tion allows one to determine the position of that base. The dideoxynucleo-tide lacks a 3'-OH group on the ribose ring and as a consequence, DNA synthesis is terminated because the DNA polymerase will not add another nucleotide to the growing strand since a 3'-OH group is absolutely required for DNA chain elongation.
Since a particular reaction will contain millions of growing DNA strands, a “nested set” of fragments is obtained with each fragment being terminated at a different position corresponding to the random incorporation of the dideoxynucleotide.
The Role of Genes in Cancer
11In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
The Exp
erimen
t
DeducedSequence
GAGCCAGCGAGTA
FragmentSize
31302928272625242322212019
C T A G
3’
5’
Figure 4: Determining the sequence of a DNA fragment.
Figure 4 shows a “nested set” of fragments produced for a hypothetical DNA sequence. The "G" reaction contains the standard reaction mixture (dATP, dCTP, dGTP, dTTP, the DNA polymerase, the appropriate buffer for DNA synthesis, 32P labeled or fl uorescent tagged nucleotide(s) and a small amount of dideoxyGTP (ddGTP). The ddGTP (dideoxyGTP) random and infrequent incorporation will produce a “nested set” of fragments which terminate with a ddGTP. The “nested set” is complimentary to the sequence. Similar “nested sets” are produced in the separate “A”, “T”, and “C” reac-tions. For example, the “A” “nested set” would terminate with a ddATP.
It should be apparent that together the “G, A, T, C” “nested sets” con-tain fragments ranging in size successively from 19 to 31 nucleotides for the hypothetical sequence in Figure 3. In the fi gure the “G” reaction contains fragments of 21, 23, 25, 29 and 31 nucleotides in length. The fi rst eighteen nucleotides are contained in the synthetic DNA sequenc-ing primer which are not shown. The rest are added during de novo synthesis by the DNA polymerase.
The reaction products from the G, A, T, and C reactions are separated by electro-phoresis using a thin and long vertical polyacrylamide gel. DNA sequencing gels
resolve fragments which differ in size by a single nucleotide. After elec-trophoretic separation is complete, the sequence is determined by either radioactivity or fl uorescence. If radioactivity was used, autoradiography is performed. The polyacrylamide gel is placed into direct contact with a sheet of x-ray fi lm. Since the DNA fragments are radioactively labeled with 32P, their position can be detected by a dark exposure band on the sheet of x-ray fi lm. Recent advances have also made it possible to automate DNA sequenc-ing and to avoid the use of isotopic 32P.
The Role of Genes in Cancer
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
12
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #Th
e Ex
per
imen
t
EXPERIMENT OBJECTIVE:
In this experiment, you will construct a family pedigree that is suspected to have the classic Li-Fraumeni syndrome. DNA samples which have been enzy-matically digested will be separated by electrophoresis on an agarose gel as an independent diagnostic test. DNA sequencing x-rays simulating p53 hot spot sequences will also be examined and mutations will be identifi ed.
LABORATORY SAFETY
1. Gloves and goggles should be worn routinely as good laboratory prac-tice.
2. Exercise extreme caution when working with equipment that is used in conjunction with the heating and/or melting of reagents.
3. DO NOT MOUTH PIPET REAGENTS - USE PIPET PUMPS.
4. Exercise caution when using any electrical equipment in the laboratory.
5. Always wash hands thoroughly with soap and water after handling reagents or biological materials in the laboratory.
LABORATORY NOTEBOOK RECORDINGS:
Address and record the following in your laboratory notebook or on a sepa-rate worksheet.
Before starting the Experiment:
• Write a hypothesis that refl ects the experiment. • Predict experimental outcomes.
During the Experiment:
• Record (draw) your observations, or photograph the results.
Following the Experiment:
• Formulate an explanation from the results. • Determine what could be changed in the experiment if the experi-
ment were repeated. • Write a hypothesis that would refl ect this change.
Experiment Overview and General Instructions
13In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
The Exp
erimen
t
Module One: Construction of a Family Pedigree
A fi rst step in the search and assignment of Li-Fraumeni syndrome is to es-tablish the family pedigree of the patient.
The fi rst part of the experiment is based on the information made avail-able as part of a diagnosis by the family physician and the oncologist. The pedigree information that you will develop is for a young woman who is suspected to have the Li-Fraumeni syndrome.
INFORMATION FOR DEVELOPING THE FAMILY PEDIGREE:
Upon monthly breast self-examination, Valerie Brown, age 36, found a small irregular mass. She was concerned because she knew that her mother had a mastectomy when she was in her late thirties. Valerie made an appointment with her physician, who referred her to a specialist at a local cancer center, where she was diagnosed as having breast cancer. As part of the medical work-up, the oncologist had inquired about her family history of cancer. Upon consultation with her mother, Valerie learned that her father and his family appeared to be free of cancer. However, in Valerie's mother's family, several cases of cancer have occurred.
With the information given below, chart the family pedigree.
• Her mother, Diane, was diagnosed and treated for breast cancer at the age of 39.
• Valerie did not know that Diane had a sister, Mabel, who died at age 2
of a brain tumor.
• Diane's brother, James (age 40), underwent surgery, followed by chemo-therapy for colon cancer.
• Her maternal grandmother, Elsie, died at age 42 from bilateral breast cancer.
• Her maternal grandfather, Elmer, was free of cancer and is 88 years old.
• Her maternal cousin, Patrick (son of James), died of brain cancer at 14.
• Her cousin (Patrick's sister), Jane, was diagnosed with childhood leuke-mia and subsequently died at age 2 .
• Patrick's two other brothers, Richard (age 28) and Curtis (age 30), are in good health and free of cancer.
• Valerie's sister, Nancy (age 38), is free of cancer.
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
14
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #Th
e Ex
per
imen
t
Module Two: Separation of DNA Fragments
The familial pedigree in Module 1 strongly suggests Li-Fraumeni syndrome. In such a case, a secondary diagnostic test is normally conducted. In this scenario, Valerie provides a sample of blood and tumor biopsy tissue to con-duct DNA analysis for the p53 gene. Normally the procedure is to amplify the gene using polymerase chain reaction. This is followed by one of several methods to detect the presence of a point mutation at the hot spots.
In this simulation experiment, Valerie's DNA has already been digested with a restriction enzyme that recognizes the mutant sequence at the simulated hot spot site at nucleotide 165 which is also the palindrome CAGCTG for the restriction enzyme. This restriction enzyme was used as a probe to cut the simulated amplifi ed gene for Valerie’s DNA sample, together with a normal control and a set of standard DNA marker fragments. Digestion of the normal amplifi ed DNA will give a characteristic "control" DNA fragment banding pattern. The DNA obtained from blood lymphocytes will give an altered band pattern representing one normal allele and the second which is the mutant. The DNA analysis from the tumor tissue will show only the pattern for the tumor allele. The predigested DNA samples with the control wild type and DNA markers will be separated by agarose gel electrophoresis, stained, and then analyzed.
• Nancy's son, Michael, was diagnosed at age 3 as having sarcoma. Re-cently, at age 18, he was diagnosed as having osteosarcoma.
• Nancy's other son, John (age 16), and daughter, Jessica (age 8), are free of cancer.
Valerie has fi ve children:
• Justin (age 16) • Sheila (age 14) • Robert (age 10) • Angela (age 8) • Anthony (age 6).
All the children show no signs of cancer at this time. Valerie has requested that DNA sequencing be done for each of her children (see Module Three).
Module One: Construction of a Family Pedigree
15In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
The Exp
erimen
t
AGAROSE GEL REQUIREMENTS FOR THIS EXPERIMENT
• Recommended gel size: 7 x 7 cm
• Number of sample wells required: 5
• Agarose gel concentration: 0.8%
PREPARING THE AGAROSE GEL
1. Close off the open ends of a clean and dry gel bed (casting tray) by us-ing rubber dams or tape.
2. Place a well-former template (comb) in the fi rst set of notches at the end of the bed. Make sure the comb sits fi rmly and evenly across the bed.
3. To a 250 ml fl ask or beaker, add agarose powder and buffer as indicated in the Reference Tables (Appendix A) provided by your instructor. Swirl the mixture to disperse clumps of agarose powder.
4. With a marking pen, indicate the level of the solution volume on the outside of the fl ask.
5. Heat the mixture using a microwave oven or burner to dissolve the aga-rose powder.
6. Cool the agarose solution to 60°C with careful swirling to promote even dissipation of heat. If detectable evaporation has occurred, add distilled water to bring the solution up to the original volume marked in step 4.
After the gel is cooled to 60°C:
7. Place the bed on a level surface and pour the cooled agarose solution into the bed.
8. Allow the gel to completely solidify. It will become fi rm and cool to the touch after approximately 20 minutes.
9. After the gel is solidifi ed, be careful not to damage or tear the wells while removing the rubber dams or tape and comb(s) from the gel bed.
10. Place the gel (on its bed) into the electrophoresis chamber, properly oriented, centered and level on the platform.
11. Fill the electrophoresis apparatus chamber with the appropriate amount of diluted (1x) electrophoresis buffer (refer to Table B on the instruction sheet from the Appendix provided by your instructor).
Module Two: Separation of DNA Fragments
If you are unfamiliar with agarose gel preparation and electrophoresis, detailed instructions and helpful resources are available at www.edvotek.com
Important Note
Continue heating until the fi nal solution appears clear (like water) without any un-dissolved particles. Check the solution carefully. If you see "crystal" particles, the agarose is not completely dissolved.
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
16
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #Th
e Ex
per
imen
t
LOADING THE SAMPLES
This experiment is designed for staining with InstaStain® Ethidium Bromide. The amount of sample that should be loaded is 18-20 µl. Make sure the gel is completely submerged under buffer before loading the samples and con-ducting electrophoresis.
Module Two: Separation of DNA Fragments
Reminder:
Before loading the samples, make sure the gel is properly oriented in the apparatus chamber.
+Black Red
Sample wells
–
Electrophoresis can be completed in 15-20 minutes under optimal conditions. For Time and Voltage recommendations, refer to Table C (Appendix A).
LOADING DNA SAMPLES
12. Heat the DNA fragments (tubes A-E) for two minutes at 65°C. Allow samples to cool for a few minutes before gel loading.
13. Load 18-20 µl of each DNA sample in the following manner:
Lane Tube 1 A Standard DNA Fragments 2 B Control DNA 3 C Patient Peripheral Blood DNA 4 D Patient Tumor DNA 5 E Patient Breast Normal DNA
RUNNING THE GEL
14. After the DNA samples are loaded, properly orient the cover and care-fully snap it onto the electrode terminals.
15. Insert the plugs of the black and red wires into the corresponding inputs of the power source.
16. Set the power source at the required voltage and conduct electrophore-sis for the length of time determined by your instructor.
17. Check to see that current is fl owing properly - you should see bubbles forming on the two platinum electrodes.
18. After the electrophoresis is completed, disconnect the power and re-move the gel from the bed for staining.
STAINING AND VISUALIZATION OF DNA After electrophoresis, agarose gels require staining to visualize the separated DNA samples. Your instructor will provide instructions for DNA staining with InstaStain® Ethidium Bromide (Appendix C).
17In Search of the Cancer Gene
314EDVO-Kit #
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
The Exp
erimen
t
Module Three: Analysis of Autorads to Search for p53 Mutagens
In this part of the experiment, x-ray results of the wild p53 and samples from Valerie's fi ve children will be read to determine whether or not there are mutations.
Valerie's children Ages Autorad #
Justin 16 1 Sheila 14 2 Robert 10 3 Angela 8 4 Anthony 6 5
1. For each of Valerie's children, obtain the appropriate sample autoradio-graph and place it on a light box to enhance visualization.
2. The sequencing reactions have all been loaded in order: G-A-T-C.
3. Begin analysis of the DNA sequence at the bottom of the autoradio-graph with the circled band, which is an A.
4. Compare the deduced sequence to the wild type sequence shown in the box below.
5. Identify the location of the potential mutant nucleotide. What was the mutation? Is there more than one mutation?
6. Based on the information obtained from the x-rays, which of Valerie's children have a mutation in their DNA sequence?
Note: This is a simulation and the DNA sequence is not that of p53. The principles of reading DNA sequences and fi nding the point mutation is the same.
Wild Type sequence:
5'-AGCTTGGCTGCAGGTCGACGGATCCCCAGGAATTCGTAAT-3'
Duplication of this document, in conjunction with use of accompanying reagents, is permitted for classroom/labora-tory use only. This document, or any part, may not be reproduced or distributed for any other purpose without the written consent of EDVOTEK, Inc. Copyright © 1997, 1998, 1999, 2001, 2002, 2006 EDVOTEK, Inc., all rights reserved EVT 001227K
18
314In Search of the Cancer Gene
The Biotechnology Education Company® • 1-800-EDVOTEK • www.edvotek.com
EDVO-Kit #Th
e Ex
per
imen
t
Answer the following study questions in your laboratory notebook or on a separate worksheet.
1. What is the difference between tumor suppressors and oncogenes?
2. What are the effects of hot spots in p53 protein structure?
3. Why does Valerie's tumor DNA sample have fewer bands than the pe-ripheral blood?
4. What is the purpose of the control lane?
5. Can a physician proceed with diagnosis based on molecular biology data?
Study Questions
31
314EDVO-Kit #Material Safety Data Sheets
Full size (8.5 x 11”) pdf copy of MSDS available at www.edvotek.com or by request.
Mat
eria
l Saf
ety
Dat
a Sh
eet
May
be
use
d t
o c
om
ply
wit
h O
SHA
's H
azar
d C
om
mu
nic
atio
nSt
and
ard
. 29
CFR
191
0.12
00 S
tan
dar
d m
ust
be
con
sult
ed f
or
spec
ific
req
uir
emen
ts.
IDEN
TITY
(A
s U
sed
on
Lab
el a
nd
Lis
t)N
ote
: B
lan
k sp
aces
are
no
t p
erm
itte
d.
If a
ny
item
is n
ot
app
licab
le, o
r n
o in
form
atio
n is
ava
ilab
le, t
he
spac
e m
ust
b
e m
arke
d t
o in
dic
ate
that
.
Sect
ion
IM
anu
fact
ure
r's
Nam
e
Sect
ion
II -
Haz
ard
ou
s In
gre
die
nts
/Id
enti
fy In
form
atio
n
Emer
gen
cy T
elep
ho
ne
Nu
mb
er
Tele
ph
on
e N
um
ber
fo
r in
form
atio
n
Dat
e Pr
epar
ed
Sig
nat
ure
of
Prep
arer
(o
pti
on
al)
Ad
dre
ss (
Nu
mb
er, S
tree
t, C
ity,
Sta
te,
Zip
Co
de)
EDV
OTE
K, I
nc.
1467
6 R
oth
geb
Dri
veR
ock
ville
, MD
208
50
Haz
ard
ou
s C
om
po
nen
ts [
Spec
ific
C
hem
ical
Iden
tity
; C
om
mo
n N
ame(
s)]
O
SHA
PEL
AC
GIH
TLV
Oth
er L
imit
s R
eco
mm
end
ed%
(O
pti
on
al)
(301
) 25
1-59
90
(301
) 25
1-59
90
Bo
ilin
g P
oin
tSe
ctio
n II
I - P
hys
ical
/Ch
emic
al C
har
acte
rist
ics
Un
usu
al F
ire
and
Exp
losi
on
Haz
ard
s
Spec
ial F
ire
Fig
hti
ng
Pro
ced
ure
s
Vap
or
Pres
sure
(m
m H
g.)
Vap
or
Den
sity
(A
IR =
1)
Solu
bili
ty in
Wat
er
Ap
pea
ran
ce a
nd
Od
or
Sect
ion
IV -
Ph
ysic
al/C
hem
ical
Ch
arac
teri
stic
sFl
ash
Po
int
(Met
ho
d U
sed
)
Exti
ng
uis
hin
g M
edia
Flam
mab
le L
imit
sU
ELLE
L
Mel
tin
g P
oin
t
Evap
ora
tio
n R
ate
(Bu
tyl A
ceta
te =
1)
Spec
ific
Gra
vity
(H
0 =
1)
2
Ag
aro
se
10/0
5/06
This
pro
du
ct c
on
tain
s n
o h
azar
do
us
mat
eria
ls a
s d
efin
ed b
y th
e O
SHA
Haz
ard
Co
mm
un
icat
ion
Stan
dar
d.
CA
S #9
012-
36-6
For
1% s
olu
tio
n 1
94 F
N
o d
ata
N
o d
ata
No
dat
a
No
dat
a
No
dat
a
Inso
lub
le -
co
ld
W
hit
e p
ow
der
, no
od
or
N.D
. = N
o d
ata
No
dat
a
N
.D.
N.D
.
Wat
er s
pra
y, d
ry c
hem
ical
, car
bo
n d
ioxi
de,
hal
on
or
stan
dar
d f
oam
Poss
ible
fir
e h
azar
d w
hen
exp
ose
d t
o h
eat
or
flam
e
No
ne
ED
VO
TE
K®
Stab
ility
Sect
ion
V -
Rea
ctiv
ity
Dat
aU
nst
able
Sect
ion
VI -
Hea
lth
Haz
ard
Dat
a
Inco
mp
atib
ility
Co
nd
itio
ns
to A
void
Ro
ute
(s)
of
Entr
y:In
hal
atio
n?
Ing
esti
on
?Sk
in?
Oth
er
Stab
le
Haz
ard
ou
s Po
lym
eriz
atio
nM
ay O
ccu
rC
on
dit
ion
s to
Avo
id
Will
No
t O
ccu
r
Hea
lth
Haz
ard
s (A
cute
an
d C
hro
nic
)
Car
cin
og
enic
ity:
NTP
?O
SHA
Reg
ula
tio
n?
IAR
C M
on
og
rap
hs?
Sig
ns
and
Sym
pto
ms
of
Exp
osu
re
Med
ical
Co
nd
itio
ns
Gen
eral
ly A
gg
rava
ted
by
Exp
osu
re
Emer
gen
cy F
irst
Aid
Pro
ced
ure
s
Sect
ion
VII
- Pr
ecau
tio
ns
for
Safe
Han
dlin
g a
nd
Use
Step
s to
be
Take
n in
cas
e M
ater
ial i
s R
elea
sed
fo
r Sp
illed
Was
te D
isp
osa
l Met
ho
d
Prec
auti
on
s to
be
Take
n in
Han
dlin
g a
nd
Sto
rin
g
Oth
er P
reca
uti
on
s
Sect
ion
VIII
- C
on
tro
l Mea
sure
s
Ven
tila
tio
nLo
cal E
xhau
stSp
ecia
l
Mec
han
ical
G
en. d
iluti
on
ven
tila
tio
n
Res
pir
ato
ry P
rote
ctio
n (
Spec
ify
Typ
e)
Pro
tect
ive
Glo
ves
Oth
er P
rote
ctiv
e C
loth
ing
or
Equ
ipm
ent
Wo
rk/H
ygie
nic
Pra
ctic
es
Eye
Pro
tect
ion
Haz
ard
ou
s D
eco
mp
osi
tio
n o
r B
ypro
du
cts
Yes
Sp
lash
pro
of
go
gg
les
Imp
ervi
ou
s cl
oth
ing
to
pre
ven
t sk
in c
on
tact
No
neX
N
on
e
No
dat
a av
aila
ble
X
No
ne
Yes
Y
es
Yes
Inh
alat
ion
: N
o d
ata
avai
lab
le
In
ges
tio
n:
Larg
e am
ou
nts
may
cau
se d
iarr
hea
No
dat
a av
aila
ble
No
dat
a av
aila
ble
Trea
t sy
mp
tom
atic
ally
an
d s
up
po
rtiv
ely
Swee
p u
p a
nd
pla
ce in
su
itab
le c
on
tain
er f
or
dis
po
sal
No
rmal
so
lid w
aste
dis
po
sal
No
ne
No
ne
Ch
emic
al c
artr
idg
e re
spir
ato
r w
ith
fu
ll fa
cep
iece
.
ED
VO
TE
K®
Mat
eria
l Saf
ety
Dat
a Sh
eet
May
be
use
d t
o c
om
ply
wit
h O
SHA
's H
azar
d C
om
mu
nic
atio
nSt
and
ard
. 29
CFR
191
0.12
00 S
tan
dar
d m
ust
be
con
sult
ed f
or
spec
ific
req
uir
emen
ts.
IDEN
TITY
(A
s U
sed
on
Lab
el a
nd
Lis
t)N
ote
: B
lan
k sp
aces
are
no
t p
erm
itte
d.
If a
ny
item
is n
ot
app
licab
le, o
r n
o in
form
atio
n is
ava
ilab
le, t
he
spac
e m
ust
b
e m
arke
d t
o in
dic
ate
that
.
Sect
ion
IM
anu
fact
ure
r's
Nam
e
Sect
ion
II -
Haz
ard
ou
s In
gre
die
nts
/Id
enti
fy In
form
atio
n
Emer
gen
cy T
elep
ho
ne
Nu
mb
er
Tele
ph
on
e N
um
ber
fo
r in
form
atio
n
Dat
e Pr
epar
ed
Sig
nat
ure
of
Prep
arer
(o
pti
on
al)
Ad
dre
ss (
Nu
mb
er, S
tree
t, C
ity,
Sta
te,
Zip
Co
de)
EDV
OTE
K, I
nc.
1467
6 R
oth
geb
Dri
veR
ock
ville
, MD
208
50
Haz
ard
ou
s C
om
po
nen
ts [
Spec
ific
C
hem
ical
Iden
tity
; C
om
mo
n N
ame(
s)]
O
SHA
PEL
AC
GIH
TLV
Oth
er L
imit
s R
eco
mm
end
ed%
(O
pti
on
al)
(301
) 25
1-59
90
(301
) 25
1-59
90
Bo
ilin
g P
oin
t
Sect
ion
III -
Ph
ysic
al/C
hem
ical
Ch
arac
teri
stic
s
Un
usu
al F
ire
and
Exp
losi
on
Haz
ard
s
Spec
ial F
ire
Fig
hti
ng
Pro
ced
ure
s
Vap
or
Pres
sure
(m
m H
g.)
Vap
or
Den
sity
(A
IR =
1)
Solu
bili
ty in
Wat
er
Ap
pea
ran
ce a
nd
Od
or
Sect
ion
IV -
Ph
ysic
al/C
hem
ical
Ch
arac
teri
stic
sFl
ash
Po
int
(Met
ho
d U
sed
)
Exti
ng
uis
hin
g M
edia
Flam
mab
le L
imit
sU
ELLE
L
Mel
tin
g P
oin
t
Evap
ora
tio
n R
ate
(Bu
tyl A
ceta
te =
1)
Spec
ific
Gra
vity
(H
0 =
1)
2
50x
Elec
tro
ph
ore
sis
Bu
ffer
This
pro
du
ct c
on
tain
s n
o h
azar
do
us
mat
eria
ls a
s d
efin
ed b
y th
e O
SHA
Haz
ard
Co
mm
un
icat
ion
Sta
nd
ard
.
No
dat
a
No
dat
a
No
dat
a
No
dat
a
No
dat
a
No
dat
a
Ap
pre
ciab
le, (
gre
ater
th
an 1
0%)
Cle
ar, l
iqu
id, s
ligh
t vi
neg
ar o
do
r
No
dat
a
N.D
. = N
o d
ata N.D
.
N.D
.
Use
ext
ing
uis
hin
g m
edia
ap
pro
pri
ate
for
surr
ou
nd
ing
fir
e.
Wea
r p
rote
ctiv
e eq
uip
men
t an
d S
CB
A w
ith
fu
ll fa
cep
iece
op
erat
ed in
po
siti
ve p
ress
ure
mo
de.
No
ne
iden
tifi
ed
10/0
5/06
Stab
ility
Sect
ion
V -
Rea
ctiv
ity
Dat
aU
nst
able
Sect
ion
VI -
Hea
lth
Haz
ard
Dat
a
Inco
mp
atib
ility
Co
nd
itio
ns
to A
void
Ro
ute
(s)
of
Entr
y:In
hal
atio
n?
Ing
esti
on
?Sk
in?
Oth
er
Stab
le
Haz
ard
ou
s Po
lym
eriz
atio
nM
ay O
ccu
rC
on
dit
ion
s to
Avo
id
Will
No
t O
ccu
r
Hea
lth
Haz
ard
s (A
cute
an
d C
hro
nic
)
Car
cin
og
enic
ity:
NTP
?O
SHA
Reg
ula
tio
n?
IAR
C M
on
og
rap
hs?
Sig
ns
and
Sym
pto
ms
of
Exp
osu
re
Med
ical
Co
nd
itio
ns
Gen
eral
ly A
gg
rava
ted
by
Exp
osu
re
Emer
gen
cy F
irst
Aid
Pro
ced
ure
s
Sect
ion
VII
- Pr
ecau
tio
ns
for
Safe
Han
dlin
g a
nd
Use
Step
s to
be
Take
n in
cas
e M
ater
ial i
s R
elea
sed
fo
r Sp
illed
Was
te D
isp
osa
l Met
ho
d
Prec
auti
on
s to
be
Take
n in
Han
dlin
g a
nd
Sto
rin
g
Oth
er P
reca
uti
on
s
Sect
ion
VIII
- C
on
tro
l Mea
sure
s
Ven
tila
tio
nLo
cal E
xhau
stSp
ecia
l
Mec
han
ical
(G
ener
al)
Res
pir
ato
ry P
rote
ctio
n (
Spec
ify
Typ
e)
Pro
tect
ive
Glo
ves
Oth
er P
rote
ctiv
e C
loth
ing
or
Equ
ipm
ent
Wo
rk/H
ygie
nic
Pra
ctic
es
Eye
Pro
tect
ion
Haz
ard
ou
s D
eco
mp
osi
tio
n o
r B
ypro
du
cts
X
N
on
e
Stro
ng
oxi
diz
ing
ag
ents
Car
bo
n m
on
oxi
de,
Car
bo
n d
ioxi
de
X
N
on
e
Yes
Y
es
Y
es
No
ne
No
ne
iden
tifi
ed
Irri
tati
on
to
up
per
res
pir
ato
ry t
ract
, ski
n, e
yes
No
ne
Ing
esti
on
: If
co
nsc
iou
s, g
ive
larg
e am
ou
nts
of
wat
er
Eyes
: Fl
ush
wit
h w
ater
In
hal
atio
n:
Mo
ve t
o f
resh
air
Sk
in:
Was
h w
ith
so
ap a
nd
wat
er
Wea
r su
itab
le p
rote
ctiv
e cl
oth
ing
. M
op
up
sp
ill
and
rin
se w
ith
wat
er, o
r co
llect
in a
bso
rpti
ve m
ater
ial a
nd
dis
po
se o
f th
e ab
sorp
tive
mat
eria
l.
Dis
po
se in
acc
ord
ance
wit
h a
ll ap
plic
able
fed
eral
, sta
te, a
nd
loca
l en
viro
men
tal r
egu
lati
on
s.
Avo
id e
ye a
nd
ski
n c
on
tact
.
No
ne
Yes
N
on
e
Yes
N
on
e
Yes
_Saf
ety
go
gg
les
No
ne
No
ne
Stab
ility
Sect
ion
V -
Rea
ctiv
ity
Dat
aU
nst
able
Sect
ion
VI -
Hea
lth
Haz
ard
Dat
a
Inco
mp
atib
ility
Co
nd
itio
ns
to A
void
Ro
ute
(s)
of
Entr
y:In
hal
atio
n?
Ing
esti
on
?Sk
in?
Oth
er
Stab
le
Haz
ard
ou
s Po
lym
eriz
atio
nM
ay O
ccu
rC
on
dit
ion
s to
Avo
id
Will
No
t O
ccu
r
Hea
lth
Haz
ard
s (A
cute
an
d C
hro
nic
)
Car
cin
og
enic
ity:
NTP
?O
SHA
Reg
ula
tio
n?
IAR
C M
on
og
rap
hs?
Sig
ns
and
Sym
pto
ms
of
Exp
osu
re
Med
ical
Co
nd
itio
ns
Gen
eral
ly A
gg
rava
ted
by
Exp
osu
re
Emer
gen
cy F
irst
Aid
Pro
ced
ure
s
Sect
ion
VII
- Pr
ecau
tio
ns
for
Safe
Han
dlin
g a
nd
Use
Step
s to
be
Take
n in
cas
e M
ater
ial i
s R
elea
sed
fo
r Sp
illed
Was
te D
isp
osa
l Met
ho
d
Prec
auti
on
s to
be
Take
n in
Han
dlin
g a
nd
Sto
rin
g
Oth
er P
reca
uti
on
s
Sect
ion
VIII
- C
on
tro
l Mea
sure
s
Ven
tila
tio
nLo
cal E
xhau
stSp
ecia
l
Mec
han
ical
(G
ener
al)
Res
pir
ato
ry P
rote
ctio
n (
Spec
ify
Typ
e)
Pro
tect
ive
Glo
ves
Oth
er P
rote
ctiv
e C
loth
ing
or
Equ
ipm
ent
Wo
rk/H
ygie
nic
Pra
ctic
es
Eye
Pro
tect
ion
Haz
ard
ou
s D
eco
mp
osi
tio
n o
r B
ypro
du
cts
X
N
on
e
Stro
ng
oxi
diz
ing
ag
ents
Car
bo
n m
on
oxi
de,
Car
bo
n d
ioxi
de,
nit
rog
en o
xid
es, h
ydro
gen
bro
mid
e g
as
X
N
on
e
Yes
Y
es
Yes
No
dat
a av
aila
ble
Irri
tati
on
to
mu
cou
s m
emb
ran
es a
nd
up
per
res
pir
ato
ry t
ract
No
dat
a
Trea
t sy
mp
tom
atic
ally
an
d s
up
po
rtiv
ely
Wea
r SC
BA
, ru
bb
er b
oo
ts, r
ub
ber
glo
ves
Mix
mat
eria
l wit
h c
om
bu
stib
le s
olv
ent
and
bu
rn in
a c
hem
ical
inci
ner
ato
r eq
uip
ped
aft
erb
urn
er a
nd
scr
ub
ber
Use
in c
hem
ical
fu
me
ho
od
wit
h p
rop
er p
rote
ctiv
e la
b g
ear.
Mu
tag
en
Yes
Ch
em. f
um
e h
oo
d
No
N
on
e
Ru
bb
er
C
hem
. saf
ety
go
gg
les
R
ub
ber
bo
ots
Use
in c
hem
ical
fu
me
ho
od
wit
h p
rop
er p
rote
ctiv
e la
b g
ear.
Acu
te: M
ater
ial i
rrit
atin
g t
o m
uco
us
mem
bra
nes
, up
per
res
pir
ato
ry t
ract
, eye
s, s
kin
Ch
ron
ic:
May
alt
er g
enet
ic m
ater
ial
SCB
A
Mat
eria
l Saf
ety
Dat
a Sh
eet
May
be
use
d t
o c
om
ply
wit
h O
SHA
's H
azar
d C
om
mu
nic
atio
nSt
and
ard
. 29
CFR
191
0.12
00 S
tan
dar
d m
ust
be
con
sult
ed f
or
spec
ific
req
uir
emen
ts.
IDEN
TITY
(A
s U
sed
on
Lab
el a
nd
Lis
t)N
ote
: B
lan
k sp
aces
are
no
t p
erm
itte
d.
If a
ny
item
is n
ot
app
licab
le, o
r n
o in
form
atio
n is
ava
ilab
le, t
he
spac
e m
ust
b
e m
arke
d t
o in
dic
ate
that
.
Sect
ion
IM
anu
fact
ure
r's
Nam
e
Sect
ion
II -
Haz
ard
ou
s In
gre
die
nts
/Id
enti
fy In
form
atio
n
Emer
gen
cy T
elep
ho
ne
Nu
mb
er
Tele
ph
on
e N
um
ber
fo
r in
form
atio
n
Dat
e Pr
epar
ed
Sig
nat
ure
of
Prep
arer
(o
pti
on
al)
Inst
aSta
in, I
nc.
P.O
. Bo
x 12
32W
est
Bet
hes
da,
MD
208
27
Haz
ard
ou
s C
om
po
nen
ts [
Spec
ific
C
hem
ical
Iden
tity
; C
om
mo
n N
ame(
s)]
O
SHA
PEL
AC
GIH
TLV
Oth
er L
imit
s R
eco
mm
end
ed%
(O
pti
on
al)
(301
) 25
1-59
90
(301
) 25
1-59
90
Bo
ilin
g P
oin
t
Sect
ion
III -
Ph
ysic
al/C
hem
ical
Ch
arac
teri
stic
s
Un
usu
al F
ire
and
Exp
losi
on
Haz
ard
s
Spec
ial F
ire
Fig
hti
ng
Pro
ced
ure
s
Vap
or
Pres
sure
(m
m H
g.)
Vap
or
Den
sity
(A
IR =
1)
Solu
bili
ty in
Wat
er
Ap
pea
ran
ce a
nd
Od
or
Sect
ion
IV -
Ph
ysic
al/C
hem
ical
Ch
arac
teri
stic
sFl
ash
Po
int
(Met
ho
d U
sed
)
Exti
ng
uis
hin
g M
edia
Flam
mab
le L
imit
sU
ELLE
L
Mel
tin
g P
oin
t
Evap
ora
tio
n R
ate
(Bu
tyl A
ceta
te =
1)
Spec
ific
Gra
vity
(H
0 =
1)
2
Inst
aSta
in®
Eth
idiu
m B
rom
ide
Eth
idiu
m B
rom
ide
D
ata
no
t av
aila
ble
No
dat
a
No
dat
a
No
dat
a
No
dat
a
No
dat
a
No
dat
a
Solu
ble
Ch
emic
al b
ou
nd
to
pap
er, n
o o
do
r
No
dat
a
N.D
. = N
o d
ata N.D
. N
.D.
Wat
er s
pra
y, c
arb
on
dio
xid
e, d
ry c
hem
ical
po
wd
er, a
lco
ho
l or
po
lym
er f
oam
Wea
r p
rote
ctiv
e cl
oth
ing
an
d S
CB
A t
o p
reve
nt
con
tact
wit
h s
kin
& e
yes
Emit
s to
xic
fum
es
10/0
5/06
CA
S# 1
39-3
3-3
(2,7
-Dia
min
o-1
0-Et
hyl
-9-P
hen
ylp
hen
anth
rid
iniu
m B
rom
ide)
ED
VO
TE
K®